NEW YORK (GenomeWeb News) - Molecular diagnostic test maker BioTheranostics said today that Lab21 will market and sell one of its cancer tests in the UK, Ireland, and in Middle East countries.
The BioMerieux subsidiary said that the two-year commercialization agreement covers its Theros CancerType ID cancer classifier test. The 92-gene test identifies 39 types of tumors and 64 sub-types, and is used to help doctors guide their treatment decisions for cancer patients whose tumor sites are uncertain or unknown.
"The partnership with Lab21 represents the successful transition to our second generation molecular cancer classification technology in Europe," Biotheranostics CEO Richard Ding said in a statement. "This RT-PCR based test will replace our micro-array based assay, which was licensed to Agendia in Europe."